image dons

je fais un don

RAS inhibition and COVID-19: more questions than answers ?

Colloquium "Rythme et conduction" (23 avril 2024)
Programme et inscription, c'est ici !

Bourses ACTION 2024 - Prix de Recherche JP Collet et Y Grosgogeat - PHRA 2024
M2, thèse de sciences, mobilité et soins infirmiers : deadline 15 mars - PHRA : deadline 30 mars

La Grande Journée du Coeur - Rendez-vous dans un cadre exceptionnel : l'Eglise Saint-Louis de la Pitié-Salpêtrière le jeudi 27 juin 2024
A vos agendas !

Lancet Respiratory Medecine 2021 Aug;9(8):807-809
Article disponible en consultant le site

Auteurs

Kerneis M, Montalescot G.

Abstract

Background

Since the beginning of the COVID-19 pandemic and the first reports of an increased mortality among patients with COVID-19 treated for hypertension, the potential role of renin–angiotensin system (RAS) blockers on the severity of the disease has been questioned. Although RAS blockers have been associated with better outcomes in pneumonia models, they might also upregulate the expression of angiotensin-converting enzyme 2 (ACE2) receptor, which acts as a co-receptor for human cell infection by SARS-CoV-2 through the binding with the spike protein. Following neutral and reassuring large observational studies and meta-analyses, two randomised trials have been done and published: the BRACE CORONA and the REPLACE COVID trials. Both studies concluded an absence of effect of chronic RAS blockade on the course of COVID-19, as previously observed in observational studies

[...]

The ACEI-COVID study adds more data to the existing evidence showing that RAS blockers should not be systematically discontinued in patients with COVID-19, but it leaves us also with more questions than answers.

Autres actualités

+

01/10/2023


Rationale and design of the ARAMIS trial: Anakinra versus pl...

Arch Cardiovasc Dis. 2023 Oct;116(10):460-466
+

01/09/2023


Comparison of three echo-guidance techniques in percutaneous...

Arch Cardiovasc Dis. 2023 Sep 29:S1875-2136(23)00171-7